Amyris Inc. (NASDAQ:AMRS) saw a large growth in short interest in October. As of October 31st, there was short interest totalling 7,731,396 shares, a growth of 106.5% from the October 14th total of 3,744,268 shares. Approximately 5.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 8,139,869 shares, the short-interest ratio is presently 0.9 days.

In other news, major shareholder (Mauritius) Pte Ltd Maxwell sold 2,611,233 shares of the business’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $0.89, for a total value of $2,323,997.37. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 48.70% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in AMRS. Jacobs Levy Equity Management Inc. purchased a new position in shares of Amyris during the first quarter worth approximately $269,000. KBC Group NV raised its position in shares of Amyris by 330.1% in the third quarter. KBC Group NV now owns 329,101 shares of the company’s stock worth $191,000 after buying an additional 252,589 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock worth $766,000 after buying an additional 311,142 shares during the last quarter. Hedge funds and other institutional investors own 35.75% of the company’s stock.

Shares of Amyris (NASDAQ:AMRS) opened at 0.7906 on Friday. Amyris has a 12 month low of $0.31 and a 12 month high of $1.81. The stock’s 50 day moving average price is $0.84 and its 200-day moving average price is $0.57. The firm’s market capitalization is $197.01 million.

Amyris (NASDAQ:AMRS) last released its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by $0.01. The company earned $26.50 million during the quarter, compared to analyst estimates of $33.61 million. Amyris’s revenue was up 208.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.23) EPS. On average, equities research analysts predict that Amyris will post ($0.25) EPS for the current fiscal year.

A number of equities research analysts have recently issued reports on the company. Zacks Investment Research lowered Amyris from a “buy” rating to a “hold” rating in a research report on Wednesday, October 19th. Singular Research reaffirmed a “buy” rating and set a $2.80 target price on shares of Amyris in a research report on Wednesday, September 28th.

Amyris Company Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

5 Day Chart for NASDAQ:AMRS

Receive News & Stock Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related stocks with our FREE daily email newsletter.